[Ovarian cancer--therapeutic options after the failure of the first line of treatment].
Ovarian cancer is the fifth leading cause of cancer deaths in women. The "gold standard" of the first line setting is taxanes and platinum-based chemotherapy. Despite substantial response, most women with ovarian cancer are destined to relapse, which occurs in 18-22 months. Management of recurrent ovarian cancer is still challenging. In this article we reviewed recent methods of treatment of the relapsed ovarian cancer: chemotherapy, radiotherapy and experimental approaches. Platines-derivates monotherapy seems to be the most adequate treatment for the platinum-sensitive ovarian cancer (carboplatin). Patients with platinum-refractory ovarian cancer should be considered for oral etoposide, radiotherapy or topotecan according to the current course of the disease. Once ovarian cancer recurs, cure is no longer a realistic goal. So it is important to realize, that the benefit with improved quality of life and relieving symptoms will be the main aspect of this treatment.
Jabłońska
Edyta
E
Kliniki Onkologii CM UJ w Krakowie.
Chłosta
Monika
M
Pawlega
Janusz
J
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010166:Palliative Care; D011788:Quality of Life; D013997:Time Factors; D016387:Women's Health
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D004791:Enzyme Inhibitors; D009944:Organoplatinum Compounds